-
Something wrong with this record ?
Colchicine in Acute Myocardial Infarction
SS. Jolly, MA. d'Entremont, SF. Lee, R. Mian, J. Tyrwhitt, S. Kedev, G. Montalescot, JH. Cornel, G. Stanković, R. Moreno, RF. Storey, TD. Henry, SR. Mehta, M. Bossard, P. Kala, J. Layland, B. Zafirovska, PJ. Devereaux, J. Eikelboom, JA. Cairns,...
Language English Country United States
Document type Journal Article, Randomized Controlled Trial, Multicenter Study
NLK
ProQuest Central
from 1980-01-03 to 3 months ago
Nursing & Allied Health Database (ProQuest)
from 1980-01-03 to 3 months ago
Health & Medicine (ProQuest)
from 1980-01-03 to 3 months ago
Family Health Database (ProQuest)
from 1980-01-03 to 3 months ago
Psychology Database (ProQuest)
from 1980-01-03 to 3 months ago
Health Management Database (ProQuest)
from 1980-01-03 to 3 months ago
Public Health Database (ProQuest)
from 1980-01-03 to 3 months ago
PubMed
39555823
DOI
10.1056/nejmoa2405922
Knihovny.cz E-resources
- MeSH
- C-Reactive Protein * analysis MeSH
- Stroke prevention & control MeSH
- Double-Blind Method MeSH
- Myocardial Infarction * prevention & control mortality MeSH
- Kaplan-Meier Estimate MeSH
- Colchicine * therapeutic use adverse effects MeSH
- Middle Aged MeSH
- Humans MeSH
- Recurrence MeSH
- Secondary Prevention MeSH
- Aged MeSH
- Spironolactone therapeutic use adverse effects MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Randomized Controlled Trial MeSH
BACKGROUND: Inflammation is associated with adverse cardiovascular events. Data from recent trials suggest that colchicine reduces the risk of cardiovascular events. METHODS: In this multicenter trial with a 2-by-2 factorial design, we randomly assigned patients who had myocardial infarction to receive either colchicine or placebo and either spironolactone or placebo. The results of the colchicine trial are reported here. The primary efficacy outcome was a composite of death from cardiovascular causes, recurrent myocardial infarction, stroke, or unplanned ischemia-driven coronary revascularization, evaluated in a time-to-event analysis. C-reactive protein was measured at 3 months in a subgroup of patients, and safety was also assessed. RESULTS: A total of 7062 patients at 104 centers in 14 countries underwent randomization; at the time of analysis, the vital status was unknown for 45 patients (0.6%), and this information was most likely missing at random. A primary-outcome event occurred in 322 of 3528 patients (9.1%) in the colchicine group and 327 of 3534 patients (9.3%) in the placebo group over a median follow-up period of 3 years (hazard ratio, 0.99; 95% confidence interval [CI], 0.85 to 1.16; P = 0.93). The incidence of individual components of the primary outcome appeared to be similar in the two groups. The least-squares mean difference in C-reactive protein levels between the colchicine group and the placebo group at 3 months, adjusted according to the baseline values, was -1.28 mg per liter (95% CI, -1.81 to -0.75). Diarrhea occurred in a higher percentage of patients with colchicine than with placebo (10.2% vs. 6.6%; P<0.001), but the incidence of serious infections did not differ between groups. CONCLUSIONS: Among patients who had myocardial infarction, treatment with colchicine, when started soon after myocardial infarction and continued for a median of 3 years, did not reduce the incidence of the composite primary outcome (death from cardiovascular causes, recurrent myocardial infarction, stroke, or unplanned ischemia-driven coronary revascularization). (Funded by the Canadian Institutes of Health Research and others; CLEAR ClinicalTrials.gov number, NCT03048825.).
B P Koirala Institute of Health Sciences Dharan Nepal
Cardiology Department University Hospital La Paz Madrid
Caril and Edyth Lindner Center for Research and Education Christ Hospital Health Network Cincinnati
Centre Hospitalier Universitaire de Sherbrooke Sherbrooke QC Canada
Department of Cardiology Peninsula Health Frankston VIC Australia
Department of Medicine University of Saskatchewan Moose Jaw Canada
Division of Cardiology Department of Medicine NYU Grossman School of Medicine New York
Division of Clinical Medicine University of Sheffield Sheffield United Kingdom
Dutch Network for Cardiovascular Research Utrecht the Netherlands
Hamilton Health Sciences Hamilton ON Canada
London Health Sciences Centre University of Western Ontario London Canada
Northwest Clinics Alkmaar the Netherlands
Peninsula Clinical School Central Clinical School Monash University Melbourne VIC Australia
Population Health Research Institute McMaster University Hamilton ON Canada
Radboud University Medical Center Nijmegen the Netherlands
Section of Cardiology Department of Medicine VA New York Harbor Healthcare System New York
University Clinical Center of Serbia and Faculty of Medicine University of Belgrade Belgrade
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009887
- 003
- CZ-PrNML
- 005
- 20250429134755.0
- 007
- ta
- 008
- 250415s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1056/NEJMoa2405922 $2 doi
- 035 __
- $a (PubMed)39555823
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Jolly, Sanjit S $u Population Health Research Institute, McMaster University, Hamilton, ON, Canada $u Hamilton Health Sciences, Hamilton, ON, Canada $1 https://orcid.org/0000000323292504
- 245 10
- $a Colchicine in Acute Myocardial Infarction / $c SS. Jolly, MA. d'Entremont, SF. Lee, R. Mian, J. Tyrwhitt, S. Kedev, G. Montalescot, JH. Cornel, G. Stanković, R. Moreno, RF. Storey, TD. Henry, SR. Mehta, M. Bossard, P. Kala, J. Layland, B. Zafirovska, PJ. Devereaux, J. Eikelboom, JA. Cairns, B. Shah, T. Sheth, SK. Sharma, W. Tarhuni, D. Conen, S. Tawadros, S. Lavi, S. Yusuf, CLEAR Investigators
- 520 9_
- $a BACKGROUND: Inflammation is associated with adverse cardiovascular events. Data from recent trials suggest that colchicine reduces the risk of cardiovascular events. METHODS: In this multicenter trial with a 2-by-2 factorial design, we randomly assigned patients who had myocardial infarction to receive either colchicine or placebo and either spironolactone or placebo. The results of the colchicine trial are reported here. The primary efficacy outcome was a composite of death from cardiovascular causes, recurrent myocardial infarction, stroke, or unplanned ischemia-driven coronary revascularization, evaluated in a time-to-event analysis. C-reactive protein was measured at 3 months in a subgroup of patients, and safety was also assessed. RESULTS: A total of 7062 patients at 104 centers in 14 countries underwent randomization; at the time of analysis, the vital status was unknown for 45 patients (0.6%), and this information was most likely missing at random. A primary-outcome event occurred in 322 of 3528 patients (9.1%) in the colchicine group and 327 of 3534 patients (9.3%) in the placebo group over a median follow-up period of 3 years (hazard ratio, 0.99; 95% confidence interval [CI], 0.85 to 1.16; P = 0.93). The incidence of individual components of the primary outcome appeared to be similar in the two groups. The least-squares mean difference in C-reactive protein levels between the colchicine group and the placebo group at 3 months, adjusted according to the baseline values, was -1.28 mg per liter (95% CI, -1.81 to -0.75). Diarrhea occurred in a higher percentage of patients with colchicine than with placebo (10.2% vs. 6.6%; P<0.001), but the incidence of serious infections did not differ between groups. CONCLUSIONS: Among patients who had myocardial infarction, treatment with colchicine, when started soon after myocardial infarction and continued for a median of 3 years, did not reduce the incidence of the composite primary outcome (death from cardiovascular causes, recurrent myocardial infarction, stroke, or unplanned ischemia-driven coronary revascularization). (Funded by the Canadian Institutes of Health Research and others; CLEAR ClinicalTrials.gov number, NCT03048825.).
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a kolchicin $x terapeutické užití $x škodlivé účinky $7 D003078
- 650 12
- $a infarkt myokardu $x prevence a kontrola $x mortalita $7 D009203
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a C-reaktivní protein $x analýza $7 D002097
- 650 _2
- $a spironolakton $x terapeutické užití $x škodlivé účinky $7 D013148
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a sekundární prevence $7 D055502
- 650 _2
- $a cévní mozková příhoda $x prevence a kontrola $7 D020521
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a d'Entremont, Marc-André $u Population Health Research Institute, McMaster University, Hamilton, ON, Canada $u Hamilton Health Sciences, Hamilton, ON, Canada $u Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada
- 700 1_
- $a Lee, Shun Fu $u Population Health Research Institute, McMaster University, Hamilton, ON, Canada $u Hamilton Health Sciences, Hamilton, ON, Canada
- 700 1_
- $a Mian, Rajibul $u Population Health Research Institute, McMaster University, Hamilton, ON, Canada $u Hamilton Health Sciences, Hamilton, ON, Canada
- 700 1_
- $a Tyrwhitt, Jessica $u Population Health Research Institute, McMaster University, Hamilton, ON, Canada
- 700 1_
- $a Kedev, Sasko $u Medical Faculty, University Clinic of Cardiology, University Ss. Cyril and Methodius, Skopje, North Macedonia
- 700 1_
- $a Montalescot, Gilles $u Sorbonne University, ACTION Study Group, Centre Hospitalier Universitaire Pitié-Salpêtrière Assistance Publique-Hôpitaux de Paris, Paris
- 700 1_
- $a Cornel, Jan H $u Dutch Network for Cardiovascular Research, Utrecht, the Netherlands $u Radboud University Medical Center, Nijmegen, the Netherlands $u Northwest Clinics, Alkmaar, the Netherlands
- 700 1_
- $a Stanković, Goran $u University Clinical Center of Serbia and Faculty of Medicine, University of Belgrade, Belgrade
- 700 1_
- $a Moreno, Raul $u Cardiology Department, University Hospital La Paz, Madrid
- 700 1_
- $a Storey, Robert F $u NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom $u Division of Clinical Medicine, University of Sheffield, Sheffield, United Kingdom
- 700 1_
- $a Henry, Timothy D $u Caril and Edyth Lindner Center for Research and Education, Christ Hospital Health Network, Cincinnati
- 700 1_
- $a Mehta, Shamir R $u Population Health Research Institute, McMaster University, Hamilton, ON, Canada $u Hamilton Health Sciences, Hamilton, ON, Canada
- 700 1_
- $a Bossard, Matthias $u Cardiology Division, Heart Center, Luzerner Katonsspital, and Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland
- 700 1_
- $a Kala, Petr $u University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Layland, Jamie $u Department of Cardiology, Peninsula Health, Frankston, VIC, Australia $u Peninsula Clinical School, Central Clinical School, Monash University, Melbourne, VIC, Australia
- 700 1_
- $a Zafirovska, Biljana $u Medical Faculty, University Clinic of Cardiology, University Ss. Cyril and Methodius, Skopje, North Macedonia
- 700 1_
- $a Devereaux, P J $u Population Health Research Institute, McMaster University, Hamilton, ON, Canada $u Hamilton Health Sciences, Hamilton, ON, Canada $1 https://orcid.org/000000032935637X
- 700 1_
- $a Eikelboom, John $u Population Health Research Institute, McMaster University, Hamilton, ON, Canada $u Hamilton Health Sciences, Hamilton, ON, Canada
- 700 1_
- $a Cairns, John A $u University of British Columbia and Centre for Cardiovascular Innovation, Vancouver Coastal Health, Vancouver, Canada
- 700 1_
- $a Shah, Binita $u Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine, New York $u Section of Cardiology, Department of Medicine, VA New York Harbor Healthcare System, New York
- 700 1_
- $a Sheth, Tej $u Population Health Research Institute, McMaster University, Hamilton, ON, Canada $u Hamilton Health Sciences, Hamilton, ON, Canada
- 700 1_
- $a Sharma, Sanjib K $u B.P. Koirala Institute of Health Sciences, Dharan, Nepal
- 700 1_
- $a Tarhuni, Wadea $u Department of Medicine, University of Saskatchewan, Moose Jaw, Canada
- 700 1_
- $a Conen, David $u Population Health Research Institute, McMaster University, Hamilton, ON, Canada $u Hamilton Health Sciences, Hamilton, ON, Canada
- 700 1_
- $a Tawadros, Sarah $u Population Health Research Institute, McMaster University, Hamilton, ON, Canada
- 700 1_
- $a Lavi, Shahar $u London Health Sciences Centre, University of Western Ontario, London, Canada
- 700 1_
- $a Yusuf, Salim $u Population Health Research Institute, McMaster University, Hamilton, ON, Canada
- 710 2_
- $a CLEAR Investigators
- 773 0_
- $w MED00003517 $t The New England journal of medicine $x 1533-4406 $g Roč. 392, č. 7 (2025), s. 633-642
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39555823 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429134750 $b ABA008
- 999 __
- $a ok $b bmc $g 2311335 $s 1246968
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 392 $c 7 $d 633-642 $e 20241117 $i 1533-4406 $m The New England journal of medicine $n N Engl J Med $x MED00003517
- LZP __
- $a Pubmed-20250415
